It marks the company’s first equity funds after its initial public offering fur in 2004.
The company’s statement states that Boko has issued 330 equity shares to eligible institutional buyers at an issue of issue of Rs 330 per equity share, 330 per equity share (including a premium of Rs 325 per equity share).
The company said that the interest of investors from various groups of QIP, local and international investors, which was opened on June 16 and closed on June 19, said the company said.
“Our strong response from our QIP reflects the specific strategy of Biocon and the continuous implementation investors,” said Siddharth Mittal, CEO and managing director of Biocon. “Increasing this capital strengthens our balance sheet, enables us to invest in innovation, to expand the global access to life -saving biofarmasticals, and to convert our intended healthcare solutions that suppress health inequality worldwide.”
The company said its final order book was well diverse in terms of the type of investors among domestic mutual funds, insurance companies and foreign institutional investors.
The leading investors who participated in the issue include SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life Insurance, Nippan India Mutual Fund, Mira Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI Govt.
The income from QIP will be used for alternatively convertible debentures issued by Biocon Biologics of the company’s subsidiary issued by the Goldum Sach Sach Sach Sach Sach Sach India AIF Scheme – 1 and Goldum Sach Sach Sach Sachs Sachs Indial Investment Trust AIF Scheme – 2. 2. The funds will be used for payment, pre -fixing or other financial devices and or for commitment to, pre -payment or even for others. The statement.
The post-issue shareholding of the promoter and promoter group is 54.45%.
Kotak Mahindra Capital, Bofa India Securities and Goldum Sach Sach Sach (India) Securities worked as the lead managers of QIP.
(Now you can subscribe to our Etmarkets WhatsApp channel)
